CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

After a large data breach in 2023, the value of 23andMe has plummeted, prompting concerns that the company -- and all its users' genetic data -- could soon be up for sale.

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe's co-founder ...

23andMe sale reveals what your genetic data is worth. It’s less than you think The price tag of this acquisition suggests the value of genetic data is declining. Tiffanie Drayton.

A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge greenlighted the sale of the remnants of the firm, including its wealth of ...

States sue to halt Regeneron's 23andMe acquisition, citing privacy concerns over user DNA data, as a court-ordered report on the deal's impact looms.

Before the sale, 23andMe and U.S. officials were concerned about what would happen to user data, but Regeneron has pledged to comply with data privacy practices.

The lawsuit objected to "23andMe’s sale of people’s genetic data to ensure that it isn’t misused, exposed in future data breaches, or used in ways customers never contemplated when they ...

The data, which is being sold for between $1 and $10 per account, does not contain a full genetic profile. Instead, it lists basic stats like name, sex, and birth year.

It's unclear what's next for 23andMe, but experts say there's a big incentive for corporations and researchers alike to get their hands on the company's trove of genetic data.